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Purpose: The failure of cancer treatments is partly due to the enrichment of cancer stem-like 
cells (CSLCs) that are resistant to conventional chemotherapy. A novel micelle formulation of 
oxaliplatin (OXA) encapsulated in chitosan vesicle was developed. The authors postulate that 
micelle encapsulation of OXA would eliminate both CSLCs and bulk cancer cells in colorectal 
cancer (CRC).
Experimental design: In this study, using stearic acid-g-chitosan oligosaccharide (CSO-SA) 
polymeric micelles as a drug-delivery system, OXA-loaded CSO-SA micelles (CSO-SA/OXA) 
were prepared. Intracellular uptake of CSO-SA/OXA micelles was assessed by confocal 
  microscope. The effects of free OXA, the empty carrier, and CSO-SA/OXA micelles were 
tested using human CRC cell lines in vitro and in vivo.
Results: The micelles showed excellent internalization ability that increased OXA   accumulation 
both in CRC cells and tissues. Furthermore, CSO-SA/OXA micelles could either increase 
the cytotoxicity of OXA against the bulk cancer cells or reverse chemoresistance of CSLC 
subpopulations in vitro. Intravenous administration of CSO-SA/OXA micelles effectively 
suppressed the tumor growth and reduced CD133+/CD24+ cell (putative CRC CSLC markers) 
compared with free OXA treatment, which caused CSLC enrichment in xenograft tumors 
(P , 0.05).
Conclusion: The results of this study indicate that CSO-SA micelle as a drug-delivery carrier 
is effective for eradicating CSLCs and may act as a new option for CRC therapy.
Keywords: polymeric micelle, chemotherapy resistance, tumor
Introduction
Colorectal cancer (CRC) is a prevalent disease worldwide and remains one of the 
leading causes of mortality. An emerging paradigm has revealed that cancers including 
CRC may be a stem cell disease.1–4 Cancer stem-like cells (CSLCs) are a subpopulation 
of cells within tumors that have self-renewal and pluripotent capabilities, responsible 
for tumor initiation, growth, and metastasis. Current approaches for isolation and 
identification of CSLCs are based on the expression of particular biomarkers or ability 
of forming spheroids, being indicative of being more tumorigenic and aggressive.5–9
Accumulating evidence has shown that the failure of conventional chemotherapy 
is closely related to the enrichment of CSLCs, which are more resistant than bulk 
cells to the treatment and drive chemoresistance.10–13 Focus has thus been on defining 
new therapeutic agents for reversal of chemotherapy resistance via targeting CSLCs. 
Even though great effort has been made in the past few decades, the effect is not 
desirable. The important fact is that non-CSLCs within a tumor can be transformed 
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to CSLCs through epithelial-mesenchymal transition (EMT) 
and maintain the disease.14,15 In addition, it is not yet clear 
what fraction of tumor cells is CSLCs and therefore needs to 
be eliminated. These points suggest that a highly desirable 
strategy is urgently needed that will target both the CSLCs 
and bulk cancer cells in tumors.16,17
Nanotechnology offers one of the innovative approaches to 
overcome these problems. Polymeric micelles with core-shell 
structure, formed by self-aggregation of amphiphilic graft or 
block copolymers, provide a significant advantage for deliver-
ing antitumor drugs to solid tumors.18–22 Moreover, polymeric 
micelles are largely accumulated in tumor tissue via the pas-
sive “enhanced permeability and retention (EPR) effect.”23,24 
Among the natural polysaccharides, the stearic acid-g-chitosan 
oligosaccharide (CSO-SA) micelles have been widely utilized 
as polymeric drug carriers due to their biocompatibility and 
biodegradability.25,26 CSO is nontoxic, low immunogenic, 
and biodegradable, obtained from the enzymatic degradation 
of chitosan. And SA also has low cytotoxicity as it is mainly 
composed of fat. CSO-SA micelles are thus used as a carrier 
for physically or chemically loading antitumor drugs, with 
excellent tumor cellular uptakes. Furthermore, micelle encap-
sulation of drug was studied to improve the antitumor activity 
and reverse multidrug resistance in xenograft tumors.27–30 For 
example, a CSO-SA-based polymeric nanosystem for oxalipla-
tin (OXA) loading has recently been reported to have obvious 
antiproliferative effects against breast cancer cells in vitro.31
However, the antitumor activity of OXA-loaded micellar 
nanoparticles in a CRC model has not yet been reported. In 
particular, OXA is now a standard chemotherapy option for 
CRC. Clinical studies have demonstrated that combined use 
of OXA with 5-fluorouracil and leucovorin for metastatic 
CRC has achieved response rates . 50% and median survival 
approaching 2 years,32,33 but nearly all responding CRCs 
eventually developed OXA resistance and progressed within 
8 months.34 Several hypotheses on OXA-resistant mecha-
nisms currently include decreased drug uptake, impaired 
DNA adduct formation, induced EMT phenotype, and proven 
insensitivity to CSLCs.13,35–37 Based on the recent assumption 
that polymeric micelles in drug-delivery systems facilitate 
antitumor drug uptake and overcome drug resistance, the 
strong indication of antitumor activity of OXA-loaded 
CSO-SA (CSO-SA/OXA) micelles in particular needs to be 
noted and explored, especially in a colorectal CSLC model. 
In this study, CSO-SA/OXA micelles were prepared and 
studied in detail to investigate whether they could eliminate 
CSLCs as well as bulk cancer cells in CRC.
Materials and methods
Synthesis and characteristics of CSO-SA
CSO-SA was prepared from a modified procedure developed 
in the laboratory (College of Pharmaceutical Science, 
Zhejiang University, China) by Fu-qiang Hu. CSO-SA was 
synthesized by esterification reaction between amine groups 
of CSO (molecular weight 18 kDa) and the carboxyl group 
of SA (C18H36O2, Shanghai Chemical Reagent Co, Shanghai, 
China) in the presence of carbodiimide (EDC). Briefly, SA 
and EDC (SA:EDC = 3:20, w/w) were dissolved in ethanol. 
The solution was stirred and heated to 80°C in order to activate 
the carboxylic acid of SA. After CSO (CSO:SA = 2.4:1.0, 
w/w) solution was added, the reaction was carried out at 80°C 
under stirring for 4 hours. The reaction solution was dialyzed 
using a dialysis membrane (molecular weight cutoff [MWCO] 
7.0 kDa) against pure water and then lyophilized. Finally, 
CSO-SA was obtained, and the degree of amino substitution 
was tested as described previously.27
The critical micelle concentration (CMC) of the synthe-
sized CSO-SA was determined by fluorescence methods. 
In brief, using pyrene as a probe, fluorescence spectra of 
CSO-SA micelles were measured by fluorometer (F-2500, 
Hitachi, Tokyo, Japan), excitation wavelength of which was 
set at 337 nm. The intensities of the emission were recorded 
at a range of 360–450 nm. The value of CMC was determined 
by the emission intensity ratio of the first peak (I1, 374 nm) 
to the third peak (I3, 385 nm).
Preparation of OXA-loaded CSO-SA 
micelles
CSO-SA/OXA micelles were prepared through thin film 
dispersed as previously reported.31 A volume of 2.5 mL of 
1 mg/mL OXA (Sigma-Aldrich, St Louis, MI) solution was 
added into CSO-SA micelle solution (OXA:CSO-SA = 1:10, 
w/w). The mixture was stirred for 30 minutes and added into 
2.5 mL   lecithin ethanol solution. The solvent was removed 
by rotary evaporation at 45°C. CSO-SA/OXA micelles were 
prepared by dissolving in 5% glucose.
Physicochemical properties  
of OXA-loaded CSO-SA micelles
The size and its distribution of CSO-SA/OXA micelles 
were measured by dynamic light scattering (DLS) using a 
Zetasizer (3000 HS, Malvern Instruments Ltd, Worcester-
shire, UK). The zeta potential of the micelles was detected 
by the Zetasizer.
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The morphological examinations of CSO-SA/OXA 
micelles were determined by transmission electron micros-
copy (TEM) (JEM-1230, JEOL, Tokyo, Japan). The samples 
were stained with 2% (w/v) phosphotungstic acid and placed 
on copper grids for viewing by TEM.
The OXA content in the drug-loaded micelles was 
detected using inductively coupled plasma mass spectrometer 
(ICP-MS) (Hitachi). In brief, the platinum (Pt) content in 
CSO-SA/OXA micelle solution and ultrafiltrated solution 
were measured, respectively. The latter solution was obtained 
from the ultracentrifugation of CSO-SA/OXA solution, using 
an ultrafilter centrifuge tube (MWCO 10 kDa; Millipore, 
Bedford, MA) centrifuged at 10,000 rpm for 10 minutes. 
Pt content in solution was determined by ICP-MS, and 
then the OXA content was calculated. OXA encapsulation 
efficiency (EE) was calculated using the following equation: 
EE = (mass of OXA encapsulated in micelle/mass of OXA 
added) × 100%.
In-vitro drug release-assay
In-vitro release profiles of OXA from the CSO-SA/OXA 
micelles were examined using the dialysis method. CSO-SA/
OXA micelles were mixed with fetal bovine serum (FBS) 
(CSO-SA/OXA:FBS = 1:9, v:v), resulting in a final OXA 
concentration of 50 µg/mL. The solution was then added 
into a dialysis bag (MWCO 7.0 kDa), and sealed to a plastic 
tube containing 10 mL of FBS. The test was conducted in an 
incubator shaker at 37°C, which was shaken horizontally at 
60 rpm. At various time points, FBS in the tube was collected 
and replaced with the fresh media. The amount of released 
drug was determined by ICP-MS. All drug-release tests were 
performed thrice.
Cell culture and spheroid formation
CRC cell lines HT29 and SW620 were purchased from 
the cell bank of the Chinese Academy of Medical Science 
(China). The HT29 cells were cultured in McCoy’s 5A 
medium (Invitrogen, Carlsbad, CA) and SW620 cells 
in Leibovitz’s L-15 medium (Invitrogen). Media were 
supplemented with 10% FBS, 100 unit/mL penicillin and 
100 µg/mL streptomycin. Cells were incubated at 37°C in a 
5% CO2 humidified incubator.
For the formation of spheroids, cells were cultured in 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(Invitrogen) basal serum-free medium supplemented with 
B27, 20 ng/mL epidermal growth factor, 10 ng/mL basic 
fibroblast growth factor (Invitrogen), 2 mg/mL bovine serum 
albumin, 100 unit/mL penicillin, and 100 µg/mL streptomycin. 
Single cells prepared from enzymatic dissociation were 
seeded in 6-well ultra low attachment plates at low densities 
(500–1000 cells/well) or in 96-well ultra low attachment 
plates at a density of 100–200 cells/well. After 10–14 days 
of suspension culture with or without drug, the number 
of spheroids was counted per 200 cells in primary seeded 
culture.
Intracellular uptake of OXA-loaded  
CSO-SA micelles
The cellular uptake studies were done as previously 
described.18 In brief, CSO-SA/OXA micelles were labeled 
with fluorescein isothiocyanate (FITC) via the reactive 
amino group of chitosan and the isothiocyanate group of 
FITC (CSO-SA/OXA:FITC = 1:8, mol/mol). Unreacted 
FITC was removed using dialysis. HT29 spheroids were 
seeded at a density of 100 cells/well in a 24-well low 
adhesion plate (Corning, New York, NY). When grown 
for 24 hours, cells were then incubated with FITC-labeled 
CSO-SA/OXA micelle solution in growth medium for an 
additional 30 minutes, 1 hour, and 2 hours, respectively. 
After incubation, the cells were washed with phosphate-
buffered saline (PBS) thrice, and then the cellular uptake 
was visualized by confocal microscope (Zeiss LSM 710, 
Carl Zeiss, Dublin, CA).
Pt accumulation studies of OXA-loaded 
CSO-SA micelles
For drug-accumulation studies, dissociated HT29 and 
SW620 spheroid cells were seeded into 5 × 104 cells/well in 
a 24-well low adhesion plate. When grown for 24 hours, cells 
were exposed to OXA and CSO-SA/OXA micelles for vari-
ous periods (2 hours, 4 hours, or 8 hours). After incubation, 
all cells were washed with ice-cold PBS thrice, harvested, 
and dissolved in pure water. Total cellular Pt content was 
determined by ICP-MS, and drug accumulation was then 
calculated.
The drug-accumulation studies of tumor tissues were 
investigated in xenograft tumors. When the tumors reached 
a mean diameter of 10 mm, mice were injected in the tail 
vein with OXA or CSO-SA/OXA micelle solution. At vari-
ous time points (2 hours, 8 hours, or 24 hours), mice were 
humanely euthanized and tumors were harvested. The cancer 
tissues were thoroughly washed four times in PBS solution 
and crushed in liquid nitrogen. Pt content was detected as 
above.
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Fluorescence-activated cell analyzing  
and sorting
Fluorescent-activated cell analyzing or sorting was per-
formed using standard protocols. Single cells obtained from 
cell cultures or xenograft tumors were labeled with mouse 
antihuman CD133/2-PE (Miltenyi-Biotec GmbH, Bergisch 
Gladbach, Germany) and CD24-FITC (BD Biosciences, 
San Diego, CA). Mouse immunoglobulin G was used as 
isotype control. Cells were analyzed by FACSCalibur 
machine   (Becton Dickinson, Franklin Lakes, NJ) or sorted 
by FACSAriaII (Becton Dickinson).
Viability assays
The cytotoxicities of CSO-SA micelles, OXA, and CSO-SA/
OXA micelles were assessed by 3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazolium bromide (MTS) assay using the 
CellTiter 96 Aqueous MTS (Promega, Fitchburg, WI). HT29 
and SW620 cells were seeded in 100 µL of medium at a 
density of 2 × 104 to 5 × 104 cells/well in 96-well plates. In 
order to preserve stemness of CSLCs, dissociated spheroids 
and CD133+/CD24+ cells from HT29 and SW620 were cul-
tured in 96-well low adhesion plates (Corning) containing 
stem-cell medium. After each treatment for 48 hours, the 
MTS assay was performed according to the manufacturer’s 
instructions.
In-vivo tumorigenicity assay and mouse 
treatment
All experiments involving mice were conducted in accor-
dance with the standard protocol approved by the local animal 
care committee. Dissociated HT29 and SW620 spheroid cells 
were injected subcutaneously into the flank of 4–5-week-
old female nude mice. Two weeks after the injection, mice 
carrying xenograft tumors were randomly divided into four 
groups. Each group with six mice was treated intravenously 
once a week for 4 weeks with CSO-SA/OXA micelles (OXA 
content 2 mg/kg), free OXA (2 mg/kg), CSO-SA micelles, 
or 5% glucose, respectively. Each tumor was measured 
with a caliper, and the volume calculated using the formula: 
V = 1/2 (width2 × length).
At the end of each treatment, tumors were collected 
from mouse xenografts and washed four times in PBS 
solution. After being minced into approximately 1 mm3 in 
size, enzymatic digestion was performed using 1.5 mg/mL 
collagenase type IV and 1 mg/mL hyaluronidase in medium 
RPMI (Roswell Park Memorial Institute) 1640 (Invitogen) 
at 37°C for about 1 hour. Cells were then obtained through 
a 40 µm mesh and resuspended in PBS, which was used for 
flow cytometry.
TdT-mediated dUTP nick end labeling 
(TUNEL) assay
TUNEL-reaction was performed on 10-mm thick frozen 
tissue sections using the one-step TUNEL apoptosis assay 
kit (Beyotime, Shanghai, China) according to the manu-
facturer’s instructions. In brief, samples were fixed with 
paraformaldehyde for 30 minutes and permeabilized with 
0.1% Triton® X-100 (Dow Chemical Company, Midland, MI) 
for 10 minutes. The sections were then washed in PBS and 
incubated with 5-bromo-4-chloro-3-indolyl-phosphate sub-
strate labeled with Cy-3 for 40 minutes at 37°C.   Randomly 
chosen fields were examined at ×400 magnification using 
confocal microscope.
Statistical analysis
Statistical analysis described in the experimental sections was 
done with GraphPad Prism 5.0 (GraphPad Software Inc, La 
Jolla, CA) software. Statistical significance was determined 
by one-way analysis of variance. P-values , 0.05 were 
regarded to be statistically significant in all cases.
Results
Preparation and characteristics  
of CSO-SA micelles and OXA-loaded 
CSO-SA micelles
The degree of amino substitution of the synthesized CSO-SA 
was measured by 6-trinitrobenzene sulfonic acid test, which 
was about 5.1% (Table 1). The aggregation behavior of 
CSO-SA was confirmed by fluorescence spectroscopy 
using pyrene as a probe. The value of the CMC was about 
Table 1 Characteristics of CSO-SA and CSO-SA/OXA micelles
Material Size by numbera  
(nm)
PI Zeta potential  
(mV)
DAS (%) CMC  
(mg/mL)
EE (%)
CSO-SA 25.4 ± 2.3 0.37 ± 0.01 29.9 ± 2.9 5.1 ± 0.3 0.14 –
CSO-SA/OXA 90.0 ± 7.0 0.39 ± 0.03 24.4 ± 0.4 – – 60.7 ± 1.5
Notes: Data are presented as mean ± standard deviation (n = 3). aSize represents hydrodynamic diameter of micelle.
Abbreviations: CMC, critical micelle concentration; CSO-SA, stearic acid-g-chitosan oligosaccharide; EE, encapsulation efficiency; OXA, oxaliplatin; PI, polydispersity index; 
DAS, degree of amino substitution.
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0.14 mg/mL, which was consistent with previous results.28,31 
This low CMC meant that CSO-SA could easily self-assemble 
to form micelles in aqueous medium and keep the core-shell 
structure, even under highly diluted conditions.
The mean particle size and zeta potential of CSO-SA 
micelles and CSO-SA/OXA micelles were measured by the 
Zetasizer. It was found that the CSO-SA micelles had smaller 
size (25.4 nm) and higher positive zeta potential (29.9 mV) 
in pure water. After the OXA was loaded, the size increased 
(90.0 nm) and the zeta potential decreased (24.4 mV). The 
EE of CSO-SA/OXA micelles reached about 60 wt% by the 
present preparation method (Table 1).
The size distribution of micelles was obtained by DLS, 
and the spherical morphology was detected by TEM imaging 
(Figure 1A and B). Drug-loaded micelles were obviously 
larger than that of blank micelles (P , 0.05). However, the 
size of micelles observed in the TEM images was smaller than 
that obtained by DLS. The reason might be the shrinking of 
the hydrophilic backbone in the micelles during the drying 
process of the TEM sample. On the other hand, CSO-SA/
OXA micelles were stable at room temperature or 4°C, and 
the micelles had minimal change in the particle size in stor-
age (for 2 weeks at 4°C) as detected by the Zetasizer. The 
drug-release profile of CSO-SA/OXA micelles was assessed 
using FBS (pH 7.4) as media. It was shown that about 90% 
total OXA was released from micelles at 37°C for 48 hours 
(Figure 1C).
OXA-loaded CSO-SA micelles enhancing 
Pt accumulation in cancer cells  
and tissues
The cellular uptake test was carried out in HT29 spheroids 
using FITC-labeled CSO-SA/OXA micelles. The cells were 
incubated with FITC-labeled CSO-SA/OXA micelles for 
30 minutes, 1 hour, and 2 hours, respectively. The green 
fluorescence indicated the FITC-labeled CSO-SA/OXA 
micelles had excellent rapid cellular uptake capability 
(Figure 2A). The characteristics of micelles were consistent 
with previous studies.28
The reduced drug accumulation was considered as 
a defense mechanism of tumor cells against Pt drug. To 
investigate the enhanced cytotoxicity and reversal of drug 
resistance of CSO-SA/OXA micelles, dissociated spheroids 
of HT29 and SW620 were exposed to OXA or CSO-SA/OXA 
micelles at different incubation times, and the Pt content was 
then determined using ICP-MS. Comparing with parent drug, 
the accumulation of Pt concentration increased significantly 
as OXA was loaded into CSO-SA micelles at each time point 
(Figure 2B) (P , 0.05). It was confirmed that intracellular 
delivery of OXA increased significantly via the transport 
mediated by CSO-SA micelles.
The concentration–time profiles of OXA and CSO-SA/
OXA micelles in xenograft tumor tissues were further 
  studied. The intravenous route through the tail vein was 
selected for the solution injection. It was found that the 
CSO-SA/OXA had a higher level of Pt accumulation com-
pared with free OXA at each time point in tumor tissues 
(Figure 2C) (P , 0.05).
OXA-loaded CSO-SA micelles  
effectively suppressing both CSLCs  
and the bulk cancer cells
The cytotoxicities of CSO-SA micelles, OXA, and 
CSO-SA/OXA micelles were evaluated by MTS assay. 
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(A) Size distribution of CSO-SA micelles and CSO-SA/OXA micelles. (B) TEM image 
of CSO-SA micelles and CSO-SA/OXA micelles. TEM image of micelles stained with 
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Note: Data are presented as mean ± standard deviation.
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; OXA, oxaliplatin; 
TEM, transmission electron microscopy.
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The 50% cellular growth inhibition (IC50) value of 
blank CSO-SA micelles in model cells was detected as 
320–800 µg/mL (Supplementary table 1). It meant that 
CSO-SA micelles were relatively low in toxicity and safe 
as drug carriers. The dose-response curves revealed that 
CSO-SA/OXA micelles resulted in a three- to fourfold 
decrease in the IC50 value compared with free OXA in 
HT29 and SW620 cells (Figure 3A and Supplementary 
table 1), whereas the IC50 value of CSO-SA/OXA micelles 
was about tenfold lower than that of free OXA against 
HT29 and SW620 spheroids, which were obviously OXA 
resistant (Figure 3B). It was interesting that the IC50 value 
of CSO-SA/OXA micelles varied from 7.5 to 12.0 µg/mL 
in all cells, including spheroids (Supplementary table 1). 
The effects of each treatment on the subpopulations of 
CRC cells were next examined with putative CSLC mark-
ers, including CD133 and CD24. Similar results were 
observed: CSO-SA/OXA micelles suppressed CD133+/
CD24+ cells in CRC cell lines as well (Figure 3C). Taken 
together, these findings provided the fact that CSO-SA/
OXA micelles reversed free OXA resistance of CSLCs 
and increased cytotoxicity to both CSLCs and the bulk 
cancer cells in vitro.
OXA-loaded CSO-SA micelles inhibiting 
formation of spheroids
To evaluate whether CSO-SA/OXA micelles could influence 
formation of spheroids under serum-free conditions, the ability 
of HT29 and SW620 cells to form spheroids after treatments 
was examined with different drugs for 10–14 days. As shown 
in Figure 4A, CSO-SA/OXA micelles inhibited the formation 
of spheroids under one-third of IC50. It was observed that 
not only did the number of spheroids significantly decline 
 ( Figure 4B) (P , 0.05) but the size also reduced. It was worth 
noting that the concentration of CSO-SA/OXA micelles that 
were capable of suppressing spheroid formation was threefold 
lower than that of antiproliferative effects in the MTS assay. 
These results suggested that CSO-SA/OXA micelles were able 
to decrease the spheroid formation of cancer cells in vitro.
OXA-loaded CSO-SA micelles enhancing 
antitumor efficacy and reducing CSLCs 
enrichment in vivo
To determine whether CSO-SA/OXA micelles could improve 
cytotoxicity and influence sensitivity of CSLCs as well as 
the bulk cancer cells in xenografts, dissociated spheroids of 
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Figure 2 OXA-loaded CSO-SA micelles show excellent internalization ability and enhance Pt accumulation in tumor cells and tissues. (A) Cellular uptake of fluorescein 
isothiocyanate-labeled CSO-SA/OXA micelles in HT29 spheroids was analyzed by confocal microscope. Images were obtained after cells were incubated with CSO-SA/OXA 
micelles (OXA content was 10 µg/mL) for 30 minutes, 1 hour, and 2 hours, respectively. (B) The intracellular Pt concentrations increased in HT29 and SW620 spheroids 
treated with CSO-SA/OXA micelles (OXA content was 10 µg/mL) compared with free OXA (10 µg/mL) (*denotes P , 0.05). Data are presented as mean ± SD.   
(C) Intravenous administration of CSO-SA/OXA micelles increased Pt accumulation in xenograft tumors (*denotes P , 0.05). Mice received a single injection of free OXA 
(2 mg/kg) or CSO-SA/OXA micelles (OXA content was 2 mg/kg).
Note: Data are mean ± SD of three tumors per group.
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; DAPI, 4′,6-diamidino-2-phenylindole; OXA, oxaliplatin; Pt, platinum; SD, standard deviation.
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anti-proliferative effect of each drug was measured by MTS assay. (A) Bulk cells of HT29 and SW620. (B) Spheroids. (C) CD133+/CD24+ sorted cells.
Note: Data are presented as mean ± standard deviation.
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; MTS, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide; OXA, oxaliplatin.
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Figure 4 OXA-loaded CSO-SA micelles inhibit formation of spheroids. (A) HT29 and SW620 cells were incubated with OXA (3 µg/mL), CSO-SA/OXA micelles (OXA 
content was 3 µg/mL), CSO-SA micelles, or 5% glucose for 10–14 days under spheroid-forming conditions, respectively. The size of the spheroids was then visualized under 
a microscope. (B) Quantification of spheroid formation with HT29 and SW620 cells treated as in (A). 
Note: Data are presented as mean ± standard deviation (*denotes P , 0.05).
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; OXA, oxaliplatin.
HT29 and SW620 were transplanted into the flank of 4–5-
week-old female nude mice. Mice were respectively treated 
with CSO-SA/OXA micelles, OXA, CSO-SA micelles, 
or 5% glucose, and tumor growth was measured during 
the period of 5 weeks. Administration of CSO-SA/OXA 
micelles marginally inhibited tumor growth, compared with 
free OXA, CSO-SA micelles, or 5% glucose (Figure 5A and 
Supplementary table 2) (P , 0.05). In addition, it was found 
that CSO-SA/OXA micelles did not increase cytotoxicity to 
mice compared with free OXA as determined by body weight 
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(P . 0.05) (Figure 5B). These data indicated that treatment 
of CSO-SA/OXA micelles could improve therapeutic effects 
but was well tolerated in vivo.
Moreover, the tumor volume in the free-OXA group was 
smaller than that of controls, but the former group resulted 
in the enrichment of CD133+/CD24+ stem cell populations 
(  Figure 5C). In contrast, administration of CSO-SA/OXA 
micelles significantly reduced CSLC enrichment and increased 
bulk cancer cell apoptosis (Figure 6A and B). Collectively, 
these studies demonstrated that CSO-SA/OXA micelles were 
obviously more effective via directing against both colorectal 
CSLCs and bulk cancer cells in xenograft tumors.
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Figure 5 OXA-loaded CSO-SA micelles enhance antitumor efficacy and reduce cancer stem-like cell enrichment in vivo. (A) reduced size of subcutaneous colon carcinoma 
tumors derived from spheroid injection of HT29 and SW620 up to 35 days after intravenous treatment with CSO-SA/OXA micelles (OXA content was 2 mg/kg) compared 
with free OXA (2 mg/kg), CSO-SA micelles, or 5% glucose. Data are mean ± SD of six animals per group. (B) Mice were weighed during the experiment. Each individual 
mouse’s weight was set to 100% before treatment and bodyweight after treatment was correlated to initial weight. (C) A set of representative flow cytometry plots of the 
experiments. Q2 covers the region of the double-positive cells. The results show that CSO-SA/OXA micelle treatment did not lead to CD133+/CD24+ cell enrichment in 
tumors. 
Note: Data are presented as mean ± SD (*denotes P , 0.05, all others versus OXA group).
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; OXA, oxaliplatin; Q1–Q4, quadrant 1–4; SD, standard deviation.
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Figure 6 CSO-SA/OXA micelles increase apoptotic events of HT29 xenograft tumors. (A) Enhancement of apoptotic events measured by TUNEL on sections of HT29 
xenograft tumors (three per group) treated with CSO-SA/OXA micelles using confocal microscopy analysis. (B) Percentage of apoptotic events measured on sections of (A). 
A total of 1 × 105 cells per tumor were counted and the percentage of apoptotic cells calculated. 
Note: Data are presented as mean ± standard deviation (*denotes P , 0.05).
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; DAPI, 4′,6-diamidino-2-phenylindole; OXA, oxaliplatin; TUNEL, TdT-mediated dUTP nick end labeling.
Discussion
In this study, CSO-SA with 5.1% degree of amino substitution 
was synthesized successfully with low CMC. After OXA 
was loaded, the micellar size was larger in comparison with 
CSO-SA micelles. Also, the zeta potential of CSO-SA/OXA 
micelles was lower than that of CSO-SA micelles, which 
might be caused by increased volume of the micelles. In-vitro 
drug-release profiles showed that about 90% total OXA could 
be released from the micelles in 48 hours. Furthermore, the 
excellent internalization of the micelles into cancer cells was 
found in the cellular uptake test, which might result from the 
positive charge of the micellar shell and the special spatial 
structure of multiple hydrophobic domains. These findings 
provided a strong rationale to choose CSO-SA micelle as a 
drug-delivery carrier.
The objective of the study was to investigate the ability 
of CSO-SA/OXA micelles to eliminate both CSLCs and the 
bulk cancer cells in CRC. Although there is no consensus as 
to the exact criteria that define a CSLC, several approaches 
are now still to be used to isolate and characterize colorec-
tal CSLCs. Spheroid culture has been used to isolate and 
expand CSLCs based on the ability of CSLCs to grow in the 
absence of serum and without attachment to culture plates, 
whereas differentiated cells fail to survive under the same 
condition.38–40 In the present work, CSO-SA/OXA micelles 
were found to suppress the spheroid-forming capacity and 
reverse chemoresistance of spheroids of both HT29 and 
SW620 cells significantly. Another way is to apply particular 
cell markers. Even though there are several putative CSLC 
markers, coexpressions of CD133+/CD24+ cells are currently 
believed to have more characteristics of stemness than single 
markers.40 Previous studies have also proved that as few as 
2000 CD133+ cells are able to form a tumor in NOD/SCID 
mouse, whereas 10,000 CD133− cells fail.41 Therefore, in 
the present study, CD133/CD24 cells were used to evaluate 
the ability of CSO-SA/OXA micelles inhibiting CSLCs 
and non-CSLCs. The results revealed that CSO-SA/OXA 
micelles could increase the cytotoxicity of OXA against the 
CSLCs and the bulk cancer cells at the similar IC50 values 
in vitro.
Existing cancer treatments have mostly been developed 
based on animal models. The injection of human CRC cells 
into nude mice provides a reliable in-vivo model for studying 
CRC.3 It reveals that CSO-SA/OXA micelles greatly suppress 
tumor growth by increasing tumor apoptosis and reduced 
CD133+/CD24+ cell populations compared with OXA treat-
ment, which causes CSLC enrichment in xenograft tumors. 
This notion corresponded with the clinical observations of 
this study, demonstrating that the proportion of cells express-
ing CSLCs markers rose greatly after chemotherapy and 
functioned as the root of tumor recurrence. Even though avail-
able agents of selective toxicity for CSLCs were reported, 
such as salinomycin,16 and sulforaphane,42 it was still hard to 
achieve remarkable effect in eradicating tumors. The exact 
mechanism needs to be further explored.
To the best knowledge of the authors of this paper, this 
is the first study to show that CSO-SA/OXA micelles can 
directly eliminate both CSLCs and non-CSLCs in tumors, 
which provides advantages and clues to address the concern. 
The authors believe that there are two possible reasons that 
may explain the results. One is that the effective accumula-
tion and sustained release of the OXA from CSO-SA/OXA 
into the tumor tissues lead to the suppression of the tumor 
growth and the increase of apoptosis in tumor cells. Another 
explanation is that CSO-SA/OXA micelles may overcome 
adenosine triphosphate-binding cassette transporters in 
CSLCs and deliver the OXA to cell nucleus, which interca-
lates DNA and facilitates the antitumor efficacy.
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Supplementary tables
Table S1 IC50 values of CSO-SA micelles, OXA, and CSO-SA/
OXA micelles against various cells (µg/mL)
Cells OXA CSO-SA/OXA CSO-SA
HT29 cells   33.1 ± 1.2   7.6 ± 0.7 328.2 ± 46.8
SW620 cells   30.3 ± 1.8 11.5 ± 1.2 429.5 ± 36.3
HT29 spheroids   93.3 ± 8.3 11.9 ± 0.7 773.0 ± 95.3
SW620 spheroids 101.1 ± 7.1 10.5 ± 1.3 736.1 ± 55.8
HT29 cells  
(CD133+/CD24+)
  98.7 ± 6.3   9.8 ± 1.1 416.0 ± 8.6
SW620 cells  
(CD133+/CD24+)
  99.7 ± 7.2 11.1 ± 1.1 375.5 ± 6.6
Notes:  The  concentration  of  CSO-SA/OXA  micelles  was  OXA-equivalent 
concentration. Data are presented as mean ± standard deviation (n = 3).
Abbreviations: IC50, half-maximal inhibitory concentration; CSO-SA, stearic acid-
g-chitosan oligosaccharide; OXA, oxaliplatin.
Table S2 relative tumor inhibitory rate
Material T/C (%)
HT29 xenograft  
tumors
SW620 xenograft   
tumors
CSO-SA 93.4 ± 38.2 89.8 ± 10.5
OXA 42.1 ± 18.4 55.6 ± 15.6
CSO-SA/OXA 13.8 ± 10.1 23.2 ± 11.0
Notes: relative tumor inhibitory rate (T/C) was calculated as follows: 100% × 
(experimental  relative  tumor  volume/control  relative  tumor  volume).  Data  are 
presented as mean ± standard deviation (n = 6).
Abbreviations: CSO-SA, stearic acid-g-chitosan oligosaccharide; OXA, oxaliplatin.
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